Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Cancer Research Technology Limited patents


Recent patent applications related to Cancer Research Technology Limited. Cancer Research Technology Limited is listed as an Agent/Assignee. Note: Cancer Research Technology Limited may have other listings under different names/spellings. We're not affiliated with Cancer Research Technology Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Cancer Research Technology Limited-related inventors


Parg inhibitory compounds

. . . . The present invention relates to compounds of formula i that function as inhibitors of parg (poly adp-ribose glycohydrolase) enzyme activity: wherein r1a, r1b, r1c, r1d, r1e, w, x1, x2, x3, x4, x5, x6, x7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which parg activity is implicated.. ... Cancer Research Technology Limited

Therapeutic agents

. . . . . . A compound of formula (i) or a compound of formula (ii) or pharmaceutically acceptable salts thereof, wherein r1-r7 and x are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the mdm2 protein with p53.. . ... Cancer Research Technology Limited

Method for treating cancer

. . The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.. . ... Cancer Research Technology Limited

Autotaxin inhibitors

The present invention relates to compounds of formula (i): wherein r1, r2, r3, r4a, r4b, r4c, r4d, l, a, q, w and het are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (atx) enzyme activity. ... Cancer Research Technology Limited

5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “tfm compounds”) which, inter alia, inhibit checkpoint kinase 1 (chk1) kinase function. ... Cancer Research Technology Limited

Autotaxin inhibitory compounds

The present invention relates to compounds of formula i, wherein a1, a2, a3, r1, r2, r3, r4, r5, r6, l, ar and q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (atx) enzyme activity. ... Cancer Research Technology Limited

2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg

The present invention relates to compounds of formula i that function as inhibitors of parg (poly adp-ribose glycohydrolase) enzyme activity wherein r1a, r1b, r1c, r1d, r1e, w, x1, x2, x3, x4, x5, x6, x7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which parg activity is implicated.. ... Cancer Research Technology Limited

Method for detecting a genetic variant

. . . . The present invention provides a method for detecting a genetic variant in a region of interest in a dna sample comprising (i) determining, for a given sequencing platform, sequencing process and sequencing depth, the distribution of the number of reads supporting a genetic variant or plurality of genetic variants expected to be observed in the sequencing results of amplification reactions due to amplification and sequencing error (read count distribution); (ii) based on the read count distribution determined in step (i), establishing a threshold frequency at or above which the genetic variant must be observed in sequencing results of amplification reactions to assign a positive determination for the presence of the genetic variant in a given amplification reaction; (iii) partitioning the dna sample into a plurality of replicate amplification reactions, so that the mean number of amplifiable template molecules of the region of interest in a replicate amplification reaction is fewer than the reciprocal of the threshold frequency determined in step (ii); (iv) performing the amplification reactions of step (iii) and sequencing the products of amplification reactions, (v) based on step (ii) and the results of step (iv), determining the presence/absence of the genetic variant in each replicate amplification reaction; and (vi) integrating the results of (v) to determine the presence/absence of the genetic variant in the region of interest in the dna sample.. . ... Cancer Research Technology Limited

1,3,4-thiadiazole compounds and their use in treating cancer

The specification relates to compounds of formula (i), and pharmaceutically acceptable salts thereof, where q, r, r1 and r2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent gls1 mediated disease, including cancer. ... Cancer Research Technology Limited

Cd55-interaction partners and the uses thereof

. . . . The invention relates to the use of a binding member that binds to both scr1 and scr2 of cd55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to scr1 and scr2 of cd55 and neutralizing cd55 and making cancer cells susceptible to complement-mediated attack.. ... Cancer Research Technology Limited

Protease inhibition

The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment.. ... Cancer Research Technology Limited

Pyridyl piperidines

The invention provides novel substituted pyridyl piperidine compounds according to formula (i) which are wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.. . ... Cancer Research Technology Limited

Inhibiting gene expression with dsrna

The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded rna (dsrna).. . ... Cancer Research Technology Limited

[1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as taz compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit axl receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit axl receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by axl receptor tyrosine kinase, that are ameliorated by the inhibition of axl receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.. ... Cancer Research Technology Limited

02/23/17 / #20170051067

Antibodies and uses thereof

The present invention provides antibodies which bind to an epitope in the extracellular domain of human cc chemokine receptor 4 (ccr4) and which are capable of inhibiting the binding of macrophage-derived chemokine (mdc) and/or thymus and activation regulated chemokine (tarc) to ccr4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.. ... Cancer Research Technology Limited

02/09/17 / #20170037036

Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor i

The present invention relates to compounds of formula i as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (hsf1). ... Cancer Research Technology Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Cancer Research Technology Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cancer Research Technology Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###